/
BLCO
$17.05+$0.07 (+0.41%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.0B
357M shares
52-week range
$13.77 – $18.92
64% from low
Sector
OPHTHALMIC GOODS
Exchange
NYSE
CS
Change$-2.95
Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
www.bausch.com- Employees
- 13,000
- IPO / List date
- May 6, 2022
- HQ
- VAUGHAN, A6
Held by traders on TradeandTell
No one on the platform currently holds BLCO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 63,000 | $913.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BLCO yet.
